Dániel Molnár

Mr. Dániel Molnár

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
DMDániel Molnár
Dániel Molnár
ESEva Viola Suranyi
Eva Viola Suranyi
NGNikoletta Gálik
Nikoletta Gálik
Judit TothJudit Toth
Judit Toth
RHRita Hirmondó
Rita Hirmondó
Tuberculosis (TB) presents significant medical challenges, largely due to the genetic diversity of Mycobacterium tuberculosis, which enhances the resilience and resistance of the pathogen to first-line treatments. In response to the global rise of drug-resistant TB, second-line antitubercular drugs like bedaquiline (BDQ), linezolid (LZD), and clofazimine (CFZ) have become critical treatment options. Understanding the molecular changes these drugs induce is essential for optimizing TB therapy. To contribute to this effort, we investigated their impact on genome maintenance and stability using Mycobacterium smegmatis as a model organism. Using mutation accumulation assays and whole-genome sequencing, we found that the second-line antibiotics did not significantly increase mutation rates, unlike the positive control UV treatment. However, upon BDQ treatment, we detected mutations in transporter proteins and transcription factors without any increase in the minimal inhibitory concentration. Additionally, BDQ and CFZ were found to alter DNA repair pathways and reduce cellular dNTP levels, particularly CFZ, which depleted dGTP, impacting DNA synthesis. CFZ also upregulated DNA repair enzymes, enhancing error-free repairs. Despite minimal mutagenic effects, both drugs displayed distinct impacts on cellular mechanisms, suggesting additional modes of action.

22 June 2026 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
RHRita Hirmondó
Rita Hirmondó
DMDániel Molnár
Dániel Molnár
GDGergely Döbrőssy
Gergely Döbrőssy
SKSzonja T Kovács
Szonja T Kovács
BVBeata Vertessy
Beata Vertessy
Judit TothJudit Toth
Judit Toth
This study identifies a previously unrecognized interaction between Mycobacterium tuberculosis dUTPase (Dut) and the AdnAB homologous recombination complex. Using a combination of yeast two-hybrid screening, mycobacterial protein fragment complementation, and biochemical analyses with purified proteins, we show that dUTPase physically interacts with the N-terminal region of AdnA and modulates the activity of the AdnAB helicase–nuclease complex. Biochemical assays demonstrate that Dut enhances AdnAB activity on DNA substrates and alters the AdnAB–DNA interaction. Mutational perturbation of Dut, including catalytic inactivation or deletion of a mycobacteria-specific surface loop, reduces its stimulatory effect on AdnAB in vitro and decreases recombination efficiency in mycobacterial cells. Together, these results support a functional connection between dUTPase and the AdnAB DNA-processing machinery and suggest a potential link between nucleotide metabolism and DNA repair pathways.